Rallybio (RLYB) Share-based Compensation (2020 - 2026)
Rallybio (RLYB) posted Share-based Compensation of $613000.0 for Q1 2026, down 20.8% sequentially from $774000.0 in Q4 2025, and down 67.38% YoY from $1.9 million in Q1 2025.
Rallybio (RLYB) Share-based Compensation (2020 - 2026) Analysis & Trends
Rallybio has reported Share-based Compensation for 7 years, with the latest figure at $613000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 67.38% year-over-year to $613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 48.0% YoY) and the FY2025 annual result came in at $5.3 million, down 33.52% from the prior year.
- Share-based Compensation declined to $613000.0 in Q1 2026 per RLYB's latest filing, from $774000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $20.6 million in Q3 2022 and troughed at $613000.0 in Q1 2026.
- A 5-year average of $3.1 million and a median of $2.1 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 1852.61% in 2022, then slumped 87.21% in 2023.
- Over 5 years, Share-based Compensation stood at $2.3 million in 2022, then grew by 11.12% to $2.5 million in 2023, then slipped by 22.99% to $2.0 million in 2024, then plunged by 60.57% to $774000.0 in 2025, then retreated by 20.8% to $613000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $613000.0, $774000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Rallybio | 95.20 Mn | 95.20 Mn | - | 424,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 424,000.00 |
| Jun 30, 2026 | 424,000.00 |
| Mar 31, 2026 | 613,000.00 |
| Mar 31, 2026 | 613,000.00 |
| Dec 31, 2025 | 774,000.00 |
| Dec 31, 2025 | 774,000.00 |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Jun 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 1.92 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |